levofloxacin ... Chlamydia pneumoniae ... human monocytes

[Guest guest]

Diagn Microbiol Infect Dis. 2004 Nov;50(3):205-12. Related Articles,

Links

Effect of levofloxacin on the viability of intracellular Chlamydia

pneumoniae and modulation of proinflammatory cytokine production by

human monocytes.

Baltch AL, RP, Ritz WJ, Carpenter AN, Bopp LH, Michelsen PB,

Carlyn CJ, Hibbs JR.

Stratton Veterans Affairs Medical Center, Albany, NY 12208, USA.

aldona.baltch@...

Although antibiotics are known to affect the intracellular growth

of Chlamydia pneumoniae in acute infections, their efficacy in therapy

for chronic infections, including atherosclerosis, remains debatable.

Human monocyte-derived macrophages (MDM) obtained from monocytes of

healthy donors were infected with C. pneumoniae AR-39 and treated with

levofloxacin (8 microg/mL) immediately after infection (0 hours) or 24

hours after infection. Levofloxacin treatment at 24 hours, but not at

0 hours, resulted in a significant decrease in the number of C.

pneumoniae inclusions within the MDM (p < 0.05). Also decreased were

concentrations of proinflammatory cytokines tumor necrosis

factor-alpha (TNF-alpha), interleukin (IL)-1beta, IL-6, and IL-8 in

the extracellular medium (p < 0.01). Viable counts in titrations

remained similar to those in untreated controls. In summary,

levofloxacin administered to MDM at serum-attainable levels 24 hours

after C. pneumoniae infection significantly decreased inclusion counts

and proinflammatory cytokine production, but did not eliminate the C.

pneumoniae infection.

PMID: 15541607 [PubMed - indexed for MEDLINE]

[Guest guest]

Interesting. It's like the abx have a dampening effect and that's it? penny <usenethod@...> wrote: Diagn Microbiol Infect Dis. 2004 Nov;50(3):205-12. Related Articles,LinksEffect of levofloxacin on the viability of intracellular Chlamydiapneumoniae and modulation of proinflammatory cytokine production byhuman monocytes.Baltch AL, RP, Ritz WJ, Carpenter AN, Bopp LH, Michelsen PB,Carlyn CJ, Hibbs JR.Stratton Veterans Affairs Medical Center, Albany, NY 12208, USA.aldona.baltchmed (DOT) va.govAlthough antibiotics are known to affect the intracellular growthof Chlamydia pneumoniae in acute infections, their efficacy in therapyfor chronic infections, including atherosclerosis, remains debatable.Human monocyte-derived macrophages (MDM) obtained from monocytes ofhealthy donors were infected with C. pneumoniae AR-39 and treated withlevofloxacin (8 microg/mL) immediately after infection (0 hours) or 24hours after infection. Levofloxacin treatment at 24 hours, but not at0 hours, resulted in a significant decrease in the number of C.pneumoniae inclusions within the MDM (p < 0.05). Also decreased wereconcentrations of proinflammatory cytokines tumor necrosisfactor-alpha (TNF-alpha), interleukin (IL)-1beta, IL-6, and IL-8 inthe extracellular medium (p < 0.01). Viable counts in titrationsremained similar to those in untreated controls. In

summary,levofloxacin administered to MDM at serum-attainable levels 24 hoursafter C. pneumoniae infection significantly decreased inclusion countsand proinflammatory cytokine production, but did not eliminate the C.pneumoniae infection.PMID: 15541607 [PubMed - indexed for MEDLINE]